Cargando…

Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience

Background: Mepolizumab and benralizumab are monoclonal antibodies directed against anti-IL-5 and anti-IL5R, respectively, and their use reduces the exacerbation rate and maintains oral corticosteroid requirements in severe eosinophilic asthma. Previous studies have tested the therapeutic switch bet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scioscia, Giulia, Tondo, Pasquale, Nolasco, Santi, Pelaia, Corrado, Carpagnano, Giovanna Elisiana, Caiaffa, Maria Filomena, Valenti, Giuseppe, Maglio, Angelantonio, Papia, Francesco, Triggiani, Massimo, Crimi, Nunzio, Pelaia, Girolamo, Vatrella, Alessandro, Foschino Barbaro, Maria Pia, Crimi, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10342237/ https://www.ncbi.nlm.nih.gov/pubmed/37445397 http://dx.doi.org/10.3390/jcm12134362

Ejemplares similares

Real-world characteristics of “super-responders” to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis
por: Portacci, Andrea, et al.
Publicado: (2023)

Benralizumab Effectiveness in Severe Eosinophilic Asthma with Co-Presence of Bronchiectasis: A Real-World Multicentre Observational Study
por: Campisi, Raffaele, et al.
Publicado: (2023)

Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression
por: Pelaia, Corrado, et al.
Publicado: (2021)

Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy
por: Pelaia, Corrado, et al.
Publicado: (2021)

Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
por: Pelaia, Corrado, et al.
Publicado: (2023)

Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub‐phenotypes of response identified by cluster analysis
por: Di Bona, Danilo, et al.
Publicado: (2021)

Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study
por: Nolasco, Santi, et al.
Publicado: (2023)

Case Report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use
por: Nolasco, Santi, et al.
Publicado: (2020)

Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2021)

Switching from omalizumab to mepolizumab: real-life experience from Southern Italy
por: Carpagnano, Giovanna Elisiana, et al.
Publicado: (2020)

Interleukins 4 and 13 in Asthma: Key Pathophysiologic Cytokines and Druggable Molecular Targets
por: Pelaia, Corrado, et al.
Publicado: (2022)

Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma
por: Pelaia, Corrado, et al.
Publicado: (2020)

Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma
por: Pelaia, Corrado, et al.
Publicado: (2021)

Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting
por: Vitale, Carolina, et al.
Publicado: (2023)

Benralizumab in the treatment of severe asthma: design, development and potential place in therapy
por: Pelaia, Corrado, et al.
Publicado: (2018)

Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma
por: Pelaia, Corrado, et al.
Publicado: (2018)

Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities
por: Crimi, Claudia, et al.
Publicado: (2020)

High Level of Blood Eosinophils and Localization of Bronchiectasis in Patients with Severe Asthma: A Pilot Study
por: Quaranta, Vitaliano Nicola, et al.
Publicado: (2023)

Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13
por: Pelaia, Corrado, et al.
Publicado: (2022)

Novel Biological Therapies for Severe Asthma Endotypes
por: Pelaia, Corrado, et al.
Publicado: (2022)

Molecular Targets for Biological Therapies of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2020)

Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma
por: Vatrella, Alessandro, et al.
Publicado: (2022)

Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma
por: Maglio, Angelantonio, et al.
Publicado: (2021)

Effectiveness of Benralizumab in Improving the Quality of Life of Severe Eosinophilic Asthmatic Patients: Our Real-Life Experience
por: Scioscia, Giulia, et al.
Publicado: (2021)

Can Leukotriene Receptor Antagonist Therapy Improve the Control of Patients with Severe Asthma on Biological Therapy and Coexisting Bronchiectasis? A Pilot Study
por: Quaranta, Vitaliano Nicola, et al.
Publicado: (2022)

Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis
por: Pelaia, Corrado, et al.
Publicado: (2021)

Switching Biological Therapies in Severe Asthma
por: Scioscia, Giulia, et al.
Publicado: (2023)

Type 2-High Severe Asthma with and without Bronchiectasis: A Prospective Observational Multicentre Study
por: Crimi, Claudia, et al.
Publicado: (2021)

Adherence to omalizumab: A multicenter "real-world" study
por: Campisi, Raffaele, et al.
Publicado: (2020)

Real-World Experience with Benralizumab in Patients with Severe Eosinophilic Asthma: A Case Series
por: Menzella, Francesco, et al.
Publicado: (2021)

Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma
por: Pelaia, Corrado, et al.
Publicado: (2021)

Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective
por: Caminati, Marco, et al.
Publicado: (2023)

Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program
por: Campisi, Raffaele, et al.
Publicado: (2021)

Pathobiology of Type 2 Inflammation in Asthma and Nasal Polyposis
por: Pelaia, Corrado, et al.
Publicado: (2023)

Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study
por: Pelaia, Corrado, et al.
Publicado: (2023)

Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study
por: Maglio, Angelantonio, et al.
Publicado: (2023)

Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma
por: Lombardo, Nicola, et al.
Publicado: (2020)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
por: Pelaia, Corrado, et al.
Publicado: (2017)

Expression profiling of miRNA-145 and miRNA-338 in serum and sputum of patients with COPD, asthma, and asthma–COPD overlap syndrome phenotype
por: Lacedonia, Donato, et al.
Publicado: (2017)

Lung under attack by COVID-19-induced cytokine storm: pathogenic mechanisms and therapeutic implications
por: Pelaia, Corrado, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mevjc69hb7idjua4ts2jd3iq5h